Massachusetts · Medicaid and GLP-1s

Does Massachusetts Medicaid cover Wegovy or Zepbound?

Last updated

No: MassHealth (Massachusetts Medicaid) stopped covering Wegovy and Zepbound for weight loss alone on Jul 3, 2026.

Without Medicaid: the lowest cash prices in Massachusetts

  • Lowest compounded semaglutide in Massachusetts on a monthly plan, not FDA-approved

    Sunlight

    $78/mo

  • Compounded semaglutide, not FDA-approved: at a seller we link to

    Eden

    $99/mo · about $22 more per 30 days than Sunlight

  • Compounded tirzepatide, not FDA-approved: at a seller we link to

    Eden

    $129/mo · about $12 more per 30 days than FlatRx

  • F

    Lowest compounded tirzepatide in Massachusetts on a monthly plan, not FDA-approved

    FlatRx

    $118/mo

  • Next lowest per 30 days, supply stated: compounded tirzepatide in Massachusetts

    SexyMD

    $129/mo · ≈ $138 per 30 days

  • Lowest compounded liraglutide in Massachusetts on a monthly plan, not FDA-approved

    NuBloom

    $408.99/4 weeks

  • Lowest month to month, no yearly fee: compounded liraglutide in Massachusetts

    Alloy

    from $115/mo

No. MassHealth (Massachusetts Medicaid) stopped covering Wegovy and Zepbound for weight loss alone on Jul 3, 2026. The state's notice: "Effective July 3, 2026, the drugs listed below in Table 1 will no longer be covered for MassHealth members when used only for the treatment of obesity or overweight." Its Table 1 lists Saxenda (liraglutide), Wegovy (semaglutide) and Zepbound (tirzepatide), for members in fee for service and in managed care alike. (MassHealth Pharmacy Facts 276 (corrected), mass.gov/doc/pharmacy-facts-276-may-13-2026-corrected-0/download, read Nov 17, 2026). Every program must still cover some uses: in KFF's words, "coverage of GLP-1 drugs for the treatment of obesity remains optional for states, while coverage is required for drugs approved for the treatment of diabetes and, since March 2024 and December 2024, for the treatment of cardiovascular disease (Wegovy) and moderate to severe obstructive sleep apnea in adults with obesity (Zepbound), respectively" (KFF, Medicaid Coverage of and Spending on GLP-1s (January 2026), kff.org/medicaid/medicaid-coverage-of-and-spending-on-glp-1s, read Nov 17, 2026). Paying cash in Massachusetts, the lowest on a monthly plan at sellers whose own pages say they serve the state: compounded semaglutide from $78/mo at Sunlight and compounded tirzepatide from $118/mo at FlatRx. Compounded medicines are not FDA-approved.

Questions

Massachusetts Medicaid and GLP-1s: common questions

Does Massachusetts Medicaid cover Wegovy?

For weight loss alone, no: MassHealth (Massachusetts Medicaid) stopped covering Wegovy and Zepbound for weight loss alone on Jul 3, 2026. Every Medicaid program must cover Wegovy for the treatment of cardiovascular disease, KFF notes, with the state's own criteria. Wegovy not covered: the cash price at your dose

Does Massachusetts Medicaid cover Zepbound?

For weight loss alone, no: MassHealth (Massachusetts Medicaid) stopped covering Wegovy and Zepbound for weight loss alone on Jul 3, 2026. Every Medicaid program must cover Zepbound for moderate to severe obstructive sleep apnea in adults with obesity, KFF notes, with the state's own criteria. Zepbound not covered: the cash price at your dose

Does Massachusetts Medicaid cover Ozempic or Mounjaro?

For type 2 diabetes, yes: in KFF's words, "coverage of GLP-1 drugs for the treatment of obesity remains optional for states, while coverage is required for drugs approved for the treatment of diabetes and, since March 2024 and December 2024, for the treatment of cardiovascular disease (Wegovy) and moderate to severe obstructive sleep apnea in adults with obesity (Zepbound), respectively." Ozempic and Mounjaro are approved for type 2 diabetes. For weight loss alone, no: MassHealth (Massachusetts Medicaid) stopped covering Wegovy and Zepbound for weight loss alone on Jul 3, 2026.

How much do Wegovy and Zepbound alternatives cost in Massachusetts without Medicaid?

Paying cash in Massachusetts, the lowest on a monthly plan at sellers whose own pages say they serve the state: compounded semaglutide from $78/mo at Sunlight and compounded tirzepatide from $118/mo at FlatRx. Compounded medicines are not FDA-approved. Semaglutide: advertised as $78/mo at Sunlight, checked Nov 11, 2026 on sunlight.com. Tirzepatide: advertised as $118/mo at FlatRx, checked Nov 17, 2026 on flatrx.io. Liraglutide: advertised as $408.99/4 weeks at NuBloom, checked Nov 14, 2026 on mynubloom.com. Every compounded price in Massachusetts

Which states' Medicaid covers GLP-1s for weight loss?

10 programs, by KFF's January 2026 map and the states' own notices since: Delaware, Kansas, Michigan, Minnesota, Mississippi, Missouri, North Carolina, Tennessee, Virginia, and Wisconsin. Every state's Medicaid and GLP-1s

GLPcompare links out only to sellers with a referral program: if you sign up or buy through one of those links, we may earn a commission at no extra cost to you. For other sellers we show the price and the seller's address, and suggest sellers we can link to. It never changes the price you pay or the underlying data. Our default order is lowest price first, with sellers that pay us moved up, and the note under each list says which order it shows; every lowest-cost sort uses the price alone. In a price table, a partner's offer says so in its terms. The order is not a medical recommendation; a higher-placed offer is not necessarily the lowest price or the right product for you.

What a Medicaid plan covers is decided by the plan and the state, and changes; ask your plan before you rely on it. This page reports the state's and KFF's published words and sellers' own prices, not insurance or medical advice. Compounded medications are not FDA-approved. GLPcompare is an informational data platform, not a medical provider or pharmacy. Nothing here is medical advice, a diagnosis, or a recommendation to start, stop, or change any treatment. Data is aggregated from public sources and can be incomplete or out of date. Always confirm with a licensed clinician and the current FDA label.